• LCB Grants Amgen Rights to Research, Develop, and Commercialize Antibody-Drug Conjugates Combining Targets Selected by Amgen with LCB’s Proprietary ADC Platform
  • LCB Eligible to Receive up to USD 1.25 billion

DAEJEON, South Korea I December 23, 2022 ILegoChem Biosciences, Inc. (‘LCB’) (KOSDAQ:141080) announced on December 23 that it has entered into a research collaboration and license agreement with Amgen, whereby it granted Amgen rights to research, develop, and commercialize ADCs directed against up to 5 targets selected by Amgen based on LCB’s proprietary ConjuAll ADC technology.

Under the terms of the agreement, LCB is eligible to receive up to USD 1.25 billion including upfront, development and commercial milestone payments, and is also eligible for tiered royalties as a percentage of worldwide commercial sales by Amgen.

LCB’s clinical-stage ConjuAll ADC technology platform provides optimized site-specific conjugation, as well as cancer-selectively activating linker and payload technologies for ADCs. It overcomes the limitations associated with conventional technologies that produce heterogeneous ADCs with its greater potency, safety and stability, and enables the development ADCs with a wider therapeutic window and improved manufacturability.

“Amgen has a proven track record of bringing transformative medicines to market, and we are pleased that they selected our ADC technology to integrate with their efforts to develop next-generation ADCs,” said Yong-Zu Kim, LCB’s President and CEO. “This licensing agreement demonstrates LCB’s continued recognition as an industry-leading ADC player and further enhances our ability to innovate through global partnership as we build out our pipeline and accelerate our transformation into a fully-integrated oncology company.”

LCB has continued to build a robust ADC licensing deal flow with 12 transactions completed with a cumulative deal volume of over USD 5 billion.

SOURCE: LegoChem Biosciences